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Abstract
Background: Although elevated body mass index (BMI) is a predictor of better clinical outcomes in dialysis patients,
the evidence in pre-dialysis chronic kidney disease (CKD) is conflicting. Clinical measures of central obesity may be better
prognostic indicators, although investigation has been limited. The aim of this study was to assess the predictive value of
anthropometric measures for kidney failure progression and mortality in stage 3–4 CKD.
Methods: The study included newly referred stage 3–4 CKD patients at a single centre between 1/1/2008 and
31/12/2010. The associations between clinical measures of obesity (BMI, waist circumference [WC] and conicity
index [ConI]) and time to a composite primary outcome of doubling of serum creatinine, commencement of
renal replacement therapy or mortality were evaluated using the Kaplan-Meier method and multivariable Cox
regression models.
Results: Over a median follow-up period of 3.3 years, 229 (25.4 %) patients of a total population of 903 experienced the
composite primary renal outcome. When compared to normal BMI (18.5-24.9 kg/m2, n= 174), the risk of the composite
primary outcome was significantly lower in both the overweight (BMI 25–29.9 kg/m2, n = 293; adjusted hazard ratio [HR]
0.50, 95 % CI 0.33-0.75) and obese class I/II groups (BMI 30–39.9 kg/m2, n= 288; HR 0.62, 95 % CI 0.41-0.93), but not in the
obese class III group (BMI ≥40 kg/m2, n = 72; HR 0.94, 95 % CI 0.52-1.69). All-cause mortality was also lower in the
overweight group (HR 0.50, 95 % CI 0.30-0.83). WC and ConI were not associated with either the composite primary
outcome or mortality.
Conclusion: BMI in the overweight range is associated with reduced risks of kidney disease progression and all-cause
mortality in stage 3–4 CKD. WC and ConI were not independent predictors of these outcomes in this population.
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Background
Chronic kidney disease (CKD) is a growing public health
problem, with more than 10 % of the adult population in
both the United States [1] and Australia [2] estimated to
have stage 1–4 CKD. Targeting modifiable lifestyle factors,
such as obesity, has been frequently recommended as a
first line strategy for reducing the risks of kidney disease
progression and cardiovascular disease (CVD) in patients
with CKD [3–5]. However, whilst obesity has been identi-
fied as a risk factor for new onset kidney disease [6] and
mortality in the general population [7], the evidence in
CKD is conflicting. Moreover, a recent cohort study of
453,946 United States veterans with an estimated glomeru-
lar filtration rate (eGFR) < 60 ml/min per 1.73m2observed
a consistent, U-shaped association between BMI and the
outcomes of kidney disease progression and mortality, with
the best outcomes observed in overweight and mildly
obese subjects [8]. This risk factor paradox has been
deemed by some as “reverse causation”, implying that there
is unintentional illness-related weight loss which contrib-
utes to higher mortality [9].
Despite being a clinical tool which is widely used to as-
sess obesity, BMI is an unreliable measure of body fat con-
tent in patients with CKD [10]. This measure is unable to
differentiate between muscle and fat amount and distribu-
tion, and, while having reasonable correlation with body fat
percentage, BMI has poor sensitivity for diagnosing obesity
[11]. These limitations are particularly concerning in light
of the increasing evidence that abdominal obesity is a key
contributor to the health risks associated with obesity [12].
Visceral adiposity is associated with metabolic abnor-
malities and a pro-inflammatory state, which is linked with
insulin resistance and an atherogenic lipoprotein profile
[13]. Clinical measures that more precisely evaluate central
obesity, such as waist circumference (WC) and conicity
index (ConI) [14], have been more strongly associated with
clinical outcomes than BMI in the general population [15]
and in dialysis populations [16–18]. Although its prognos-
tic value in non-dialysis CKD patients has not been well
established,[19, 20] ConI, which adjusts waist circumfer-
ence for height and weight, has been linked to a number
of risk factors for metabolic syndrome [14] and kidney
disease progression, including proteinuria and systemic
inflammation [21]. It has also been linked to inflammation
[22], and poor nutritional status resulting in an increased
risk of mortality in haemodialysis patients [18].
The aim of this study was to investigate the associa-
tions between baseline anthropometric measures of
body size (BMI, WC and ConI) and the clinical out-
comes of kidney disease progression and all-cause mor-
tality in incident Australian adults with stage 3–4 CKD
referred to a specialist renal service. It was hypothe-
sised that obesity markers that were more specific for
central obesity, particularly waist circumference, would
better predict progression to the composite renal end-
point and death.
Methods
The protocol for this retrospective observational cohort
study was approved by Metro South Human Research
Ethics Committee (HREC/10/QPAH/71) and University of
Queensland School of Medicine Low Risk Ethics Commit-
tee (2014-SOMILRE-0094). General patient consent was
attained at initial referral for use of clinical data in the
Princess Alexandra Hospital (PAH) Nephrology Database.
Study population
The study population consisted of patients with CKD who
were referred by general practitioners or specialists to the
PAH Nephrology Outpatient Department between 1 January
2008 and 31 December 2010 (catchment population ap-
proximately 1 million or 23 % of Queensland’s population).
Patients included those over the age of 18 years with an
eGFR of 15-59 mL/min/1.73 m2 whose clinical data were
recorded in the PAH Nephrology Database. Patients were
excluded if they had no recorded clinical or laboratory data
from within three months of initial referral visit.
Data collection
Baseline patient data from the initial visit were obtained
from the PAH Nephrology Database and electronic med-
ical records. Recorded variables included demographics,
cause of kidney disease, comorbidities, medications, an-
thropometric measures (weight, waist circumference,
height), blood pressure and laboratory values (serum
creatinine, proteinuria, haemoglobin level, serum choles-
terol). Height, weight and WC were measured by trained
health practitioners using a standardised protocol. WC
was measured at the midpoint between the lower margin
of the last palpable rib and the top of the iliac crest.
BMI was calculated as weight (kg) divided by height (m)
squared and was categorised based on the World Health
Organisation classification: underweight (<18.5 kg/m2),
normal (18.5-24.9 kg/m2), overweight (25–29.9 kg/m2),
obese class I/II (30–39.9 kg/m2) and obese class III
(≥40 kg/m2). WC was divided into tertiles, stratified by







Serum creatinine (traceable to isotopic dilution mass
spectrometry) was measured by the Jaffe rate method
using a Beckman DxC800 general chemistry analyser
(Beckman Coulter, Brae, CA, USA). The baseline serum
creatinine value from the initial referral visit was used to
calculate an eGFR using the CKD-Epidemiology Collab-
oration (CKD-EPI) calculation [23]. Proteinuria was
assessed using urine albumin-to-creatinine ratio (ACR),
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urine protein-to-creatinine ratio (PCR) or total protein
in a 24-h urine collection and was categorised as normo,
micro- or macroproteinuria according to the recommenda-
tions of the Kidney Check Australia Taskforce [24]. Urine
protein was measured by immunoassay turbidimetric
method and urine protein was measured by pyrogallol red
and molybdate method using a Beckman DxC800 general
chemistry analyser.
Study outcomes
Patients were followed until death, loss to follow up, or 31
July 2013, whichever came first. The primary outcome of
interest in the study was a composite outcome of: 1) doub-
ling of serum creatinine; 2) initiation of renal replacement
therapy (RRT); and 3) all-cause mortality. Creatinine values
were followed through until 31 July, 2013 to determine if
there had been an increase of more than two times the
serum creatinine from initial referral, confirmed on two
readings at least four weeks apart. RRT was considered as
any form of dialysis or kidney transplantation. Patients who
were lost to follow-up in the PAH database were cross
referenced with the Australia and New Zealand Dialysis
and Transplant (ANZDATA) Registry for outcome data.
The ANZDATA Registry has complete capture of all pa-
tients in Australia and New Zealand who have commenced
RRT since 1963 (www.anzdata.org.au).
Statistical analysis
Results were expressed as frequencies and percentages
for categorical variables, mean ± standard deviation for
continuous normally distributed variables, and median
[interquartile range; IQR] for continuous variables that
were not normally distributed. Categorical data were com-
pared using chi-square tests. Continuous normally distrib-
uted data were compared using two tailed unpaired t-tests.
Continuous non-normally distributed data were compared
using Mann–Whitney tests. The association between an-
thropometric indices and time to either the composite
primary end-point or mortality were evaluated by Kaplan
Meier and multivariable Cox proportional hazards model
analyses. Each anthropometric index was analysed as a
categorical variable in the primary analysis and as a con-
tinuous variable in a sensitivity analysis. For the multivari-
able analyses, several models were examined: Model 1,
adjusted for age (continuous); Model 2, adjusted for age,
gender and race (Caucasian vs. non-Caucasian); and Model
3 included age, gender, race, cause of CKD (categorised
based on the Study of Heart and Renal Protection [SHARP]
trial [25]: diabetic nephropathy, glomerulonephritis, cystic
kidney disease and other), eGFR, proteinuria, and presence
of diabetes as a comorbidity. The data was further analysed
with stratification by gender. Patients with missing data were
excluded from multivariable analysis. P-values of <0.05 were
considered significant. Statistical analyses were performed
using SPSS Statistics version 21.
Results
Baseline characteristics
Of 1070 adult patients with CKD referred to the centre be-
tween 2008 and 2010, a total of 903 patients were included
in the study (Fig. 1). Their baseline characteristics are shown
in Table 1.
Primary composite end-point
During a median follow-up of 3.3 years, 229 patients
(25.4 %) reached a composite primary outcome, includ-
ing 15.7 % who died, 8.3 % who experienced a doubling
of their serum creatinine and 1.3 % who commenced
RRT as the initial event. The median time to the primary
end-point was 1.81 years.
On univariable analysis, patients with a BMI in the
overweight range (hazard ratio [HR] 0.565, 95 % CI 0.39-
0.81, p < 0.01) and in the class I/II obese range (HR 0.63,
95 % CI 0.44-0.90) experienced a lower hazard of the pri-
mary end-point compared with normal weight individuals
(Fig. 2, Table 2). Similar results were observed following
multivariable Cox proportional hazards model analysis
(Table 2, Fig. 3).
WC did not show a significant association with the
primary outcome as either a continuous or a categorical
variable in univariable analysis (Fig. 2, Table 2). Multivari-
able models also failed to identify a significant relationship
between WC and the primary end-point.
In univariable survival analysis, increasing ConI was pre-
dictive of a higher risk of the composite outcome (Fig. 2,
Table 2). Using ConI as a continuous variable, each 0.1 unit
increase in ConI was associated with a 28 % increased risk
of progression to the composite outcome (HR, 1.278; 95 %
CI, 1.07-1.53; P < 0.01).
Mortality
The relationship between different anthropometric mea-
sures and all-cause mortality are shown in Table 3. Those
patients in the overweight BMI category had a lower risk of
mortality. There was evidence of a U-shaped association,
with BMI ≥40 kg/m2 showing increasing risk of mortality
(Fig. 3).
There was no direct relationship between WC and
all-cause mortality in either univariable or multivariable
analysis.
ConI was also predictive of mortality (HR 1.413, 95 %
CI 1.13-1.76, P < 0.01 for each 0.1 unit increase in ConI).
This association remained significant when adjusted for
demographics but not when fully-adjusted. Increasing
ConI tertiles were also predictive of a greater risk of death
in the crude model, although significance was lost follow-
ing adjustment (Table 3).
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Gender Sub-analysis
When stratifying the data by gender (see Additional file
1: Table S1 and Table S2), a U-shaped association be-
tween BMI and the composite outcome was maintained
for crude and multivariable analysis in both males and
females. Model 2 and 3 lost statistical significance in the
female group. The U-shaped association between BMI
category and mortality was notably stronger in males
over females, where the relationship was not significant
at any level. For the composite outcome WC and ConI
was not associated with the outcome for males or fe-
males in any model.
Discussion
In the current study, BMI values in the overweight and
class I/II obese range were shown to be associated with
lower hazards of both the composite primary renal out-
come and all-cause mortality in a population of Austra-
lian adults with stage 3–4 CKD. While a high ConI was
predictive of the composite renal outcome in unadjusted
models, neither WC nor ConI showed a significant asso-
ciation with kidney disease progression or mortality in
adjusted models.
The outcome of this study, showing an inverse rela-
tionship between BMI and adverse outcomes, is similar
to findings in previous studies investigating BMI and
mortality in CKD patients [26–28]. An analysis of the
Atherosclerosis Risk in Communities (ARIC) Study data-
base demonstrated that a larger BMI was associated with
better overall survival in a CKD population but an in-
creased hazard of death in those without CKD [27].
Similarly, an evaluation of 12,534 individuals with stage
3–4 CKD participating in the Kidney Early Evaluation
Program (KEEP) showed a survival advantage for pa-
tients who were obese, although the results were no lon-
ger significant when BMI exceeded 35 kg/m2 [28]. In
contrast, the study showed no association between BMI
and rates of progression to end-stage kidney disease. In
patients with stage 3–4 CKD pooled from the Athero-
sclerosis Risk in Communities and Cardiovascular Health
Study [29], obese BMI was protective against a composite
outcome of cardiovascular events, stroke and all-cause
mortality.
The association of overweight BMI with better clinical
outcomes may be accounted for by the inability of BMI to
discriminate body composition. An elevated BMI has the
potential to represent better overall nutrition and high
muscle mass, and an increased ability to adapt to the pro-
tein energy wasting state commonly observed in kidney dis-
ease. Moreover, higher BMI has been shown as protective
Fig. 1 Derivation of the Study Cohort. PAH, Princess Alexandra Hospital; CKD, chronic kidney disease; CKD-EPI, CKD-Epidemiology Collaboration
[30]; eGFR, estimated glomerular filtration rate
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in proteinuric CKD but not in non-proteinuric CKD [30].
BMI is also unable to account for differences in body mass
distribution and the risks associated with increased visceral
adiposity. For example, an analysis by Panwar and col-
leagues [31] using the Reasons for Geographic and Racial
Differences in Stroke (REGARDS) Study data showed a
higher BMI was associated with lower ESRD risk in those
without, but not those with the metabolic syndrome. In this
analysis, controlling for WC, which was more likely to
reflect abdominal fatness, did not appreciably alter the rela-
tionship between BMI and the composite renal outcome
and only slightly attenuated the association with mortality.
Furthermore, the Tehran Lipid and Glucose Study (TLGS)
[32], found that increases in weight, BMI, WC and hip
circumference were associated with reduced mortality in
men but not women. In a gender-stratified analysis of this
Table 1 Baseline characteristics of the stage 3–4 CKD study cohort based on BMI category
Variable Total
population
Breakdown by BMI (kg/m2)
<18.5 18.5-24.9 25-29.9 30-39.9 ≥40 p-value*
(n = 903) (n = 15; 1.8 %) (n = 174; 20.7 %) (n = 293; 34.8 %) (n = 288; 34.2 %) (n = 72; 8.6 %)
Male gender 515 (57 %) 2 (13.3 %) 96 (55.2 %) 181 (61.8 %) 169 (58.7 %) 35 (48.6 %) 0.002
Age (years) 66.26 ± 13.62 56.5 ± 18.8 67 ± 15.7 68.3 ± 13 65.4 ± 12.3 61.0 ± 11.1 <0.001
Race 0.036
Caucasian 708 (78.4 %) 11 (73.3 %) 137 (78.7 %) 241 (82.3 %) 226 (78.5 %) 51 (70.8 %)
Non-Caucasian 115 (12.7 %) 2 (13.3 %) 29 (16.6 %) 24 (8.2 %) 36 (12.5 %) 14 (19.4 %)
Not stated 80 (8.9 %) 2 (13.3 %) 8 (4.6 %) 28 (9.6 %) 26 (9.0 %) 7 (9.7 %)
Cause of CKD <0.001
Diabetic nephropathy 243 (26.9 %) 0 (0.0 %) 32 (18.4 %) 59 (20.1 %) 98 (34.0 %) 33 (45.8 %)
Glomerulonephritis 75 (8.3 %) 2 (13.3 %) 17 (9.8 %) 23 (7.8 %) 20 (6.9 %) 5 (6.9 %)
Cystic kidney disease 26 (2.9 %) 1 (6.7 %) 7 (4.0 %) 13 (4.4 %) 4 (1.4 %) 1 (1.4 %)
Other 559 (61.9 %) 12 (80.0 %) 118 (67.8 %) 198 (67.6 %) 166 (57.6 %) 33 (45.8 %)
Comorbidities
Diabetes mellitus (n = 902) 387 (42.9 %) 0 (0.0 %) 49 (28.2 %) 114 (28.9 %) 146 (50.7 %) 47 (66.2 %) <0.001
CAD (n = 823) 270 (32.8 %) 1 (7.1 %) 49 (31.0 %) 93 (33.6 %) 83 (32.5 %) 21 (33.9 %) 0.351
CLD (n = 872) 117 (13.4 %) 1 (6.7 %) 21 (12.4 %) 38 (13.5 %) 36 (13.1 %) 16 (22.5 %) 0.228
CBVD (n = 870) 110 (12.6 %) 0 (0.0 %) 17 (10.2 %) 39 (13.9 %) 40 (14.2 %) 8 (11.6 %) 0.393
PVD (n = 854) 140 (16.4 %) 0 (0.0 %) 20 (12.2 %) 46 (16.5 %) 54 (19.8 %) 12 (17.9 %) 0.115
Medication use
Lipid lowering (n = 839) 402 (47.9 %) 0 (0.0 %) 72 (43.4 %) 127 (46.4 %) 143 (54.2 %) 38 (56.7 %) <0.001
ACEi/ARB (n = 839) 509 (60.7 %) 6 (40.0 %) 93 (56.0 %) 166 (60.6 %) 168 (63.6) 50 (74.6 %) 0.032
Antihypertensive (n = 822) 655 (79.7 %) 8 (53.3 %) 125 (75.8 %) 220 (80.9 %) 217 (82.2 %) 56 (84.4 %) 0.033
EPO (n = 839) 29 (3.5 %) 1 (6.7 %) 8 (4.8 %) 10 (3.6 %) 8 (3.0 %) 2 (3.0 %) 0.863
eGFR (n = 903) 37.9 ± 11.7 38.3 ± 12.2 38.3 ± 12.4 37.4 ± 11.3 37.9 ± 11.2 39.9 ± 12.0 0.573
Stage 3 654 (72.4 %) 11 (1.8 %) 124 (20.2 %) 210 (34.3 %) 212 (34.6 %) 56 (9.1 %)
Stage 4 249 (27.6 %) 4 (1.7 %) 50 (21.8 %) 83 (36.2 %) 76 (33.2 %) 16 (7.0 %)
Proteinuria (n = 780) 0.493
Microproteinuria 459 (58.8 %) 6 (54.5 %) 88 (59.5 %) 163 (64.2 %) 138 (54.3 %) 40 (59.7 %)
Macroproteinuria 293 (37.6 %) 5 (45.5 %) 56 (37.8 %) 83 (32.7 %) 104 (40.9 %) 23 (34.3 %)
Obesity measures
WC (n = 594) 101.6 ± 16.1 69.4 ± 6.9 86.1 ± 8.2 98.5 ± 8.2 111.2 ± 10.3 130.6 ± 12.6 <0.001
ConI (n = 588) 1.33 ± 0.10 1.21 ± 0.11 1.28 ± 0.09 1.33 ± 0.09 1.36 ± 0.09 1.39 ± 0.09 <0.001
Results expressed as mean ± SD or number (percentage). The number of patients with data available follows the measured variable, if total population data
not available
CKD chronic kidney disease, BMI body mass index, CAD coronary artery disease, CLD chronic lung disease, CBVD cerebrovascular disease, PVD peripheral vascular
disease, ACEi angiotensin-converting-enzyme inhibitor, ARB angiotensin II receptor blocker, EPO erythropoietin, eGFR estimated glomerular filtration rate, WC waist
circumference, ConI conicity index
*Differences between BMI categories were assessed by chi-squared test or ANOVA, depending on the data type
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Fig. 2 Kaplan-Meier Curves for Progression to the Primary Outcome for Clinical Anthropometric Measures. The primary outcome included,
doubling of serum creatinine, commencement of renal replacement therapy or all-cause mortality, with anthropometric measures of body mass
index (BMI), waist circumference (WC) and conicity index (ConI). Shown below the graphs are the number of patients at risk. a. BMI by categories
(kg/m2) [Log rank score 10.44, p = 0.034]. b. WC by tertiles [Log rank score 3.09, p = 0.21]. c. ConI by tertiles [Log rank score 4.13, p = 0.13]
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data the U-shaped association between BMI and outcomes
was found to be more pronounced in men than women but
otherwise trends were maintained.
In contrast to the findings of the current study, Evans
et al. [33] found that BMI was unrelated to time to RRT
commencement in a Swedish population of 920 CKD
patients, although the inverse relationship with mortality
was maintained. Using data from the Modification of
Diet in Renal Disease (MDRD) study [34], Madero et al.
were also unable to find an independent association
between BMI and mortality. However, in contrast to the
population in the present study, the MDRD study ex-
cluded a number of important conditions that may have
been impacted by the presence of obesity (including type 1
diabetes, insulin-dependent type 2 diabetes, autoimmune
glomerulonephritis and renal artery stenosis) and poten-
tially played a role in the different outcomes of the two
studies.
Due to the limitations of BMI as a measure of obesity, it
was hypothesised that more specific anthropometric mea-
sures of central obesity, including WC and ConI, may be
better prognostic indicators than BMI. However, neither
WC nor ConI were independent risk factors for kidney
disease progression or death. This finding contrasts with
that of a post-hoc analysis of 5,805 stage 1–4 CKD patients
participating in the REGARDS Study, which showed that
the highest WC group had an approximately two-fold
increased hazard rate for all-cause mortality [19]. The
apparent disparity in findings may be partly explained by
the differences in the study populations. The REGARDS
cohort was made up of more than 50 % individuals with
stage 1–2 CKD, whilst the present study cohort was solely
comprised of patients with stage 3 or 4 CKD. Participants
categorised with very early CKD (eGFR ≥60 mL/min/
1.73 m2) therefore may have been more closely matched
to the risk profile of the general population than individ-
uals with more advanced disease, explaining the deleteri-
ous effects of higher WC seen in their study. Furthermore,
there is conflicting evidence surrounding the reliability of
WC as a marker for visceral adiposity in CKD. Several
studies have found different levels of correlation between
visceral fat and measured WC.
In kidney disease especially, these inconsistent results
may relate to the fluid disturbances which would alter the
relationship between abdominal girth and visceral fat. Fur-
thermore, there are methodological issues with the repro-
ducibility of WC in the real world setting, more so than for
BMI [35]. Panoulas and colleagues highlighted this problem
in a study of the intra- and inter-operator variability of WC
measurements, where there were significant differences
between measurements by health practitioners [36]. While
measurements in the current study were all recorded using
a standardised protocol, there were a number of operators
involved. The lack of significant correlation between WC
and outcomes may indicate that the utility of WC is limited
in real world settings.
Table 2 Association between baseline obesity parameters and the primary outcome in stage 3–4 chronic kidney disease. Comparison
performed using Cox proportional hazards modelling to compare body mass index, waist circumference and conicity index with the
composite outcome of doubling of serum creatinine, commencement of renal replacement therapy or all-cause mortality
HR (95 % CI)
No. (%) Crude Model 1 Model 2 Model 3
Body mass index (kg/m2)
<18.5 15 (1.8) 0.54 (0.17-1.71) 0.43 (0.2-1.99) 0.57 (0.14-2.38) 0.74 (0.17-3.19)
18.5-24.9 174 (20.7) 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
25-29.9 293 (34.8) 0.57 (0.39-0.81)** 0.55 (0.38-0.79)** 0.58 (0.40-0.85)** 0.50 (0.33-0.75)**
30-39.9 288 (34.2) 0.63 (0.44-0.90)* 0.65 (0.46-0.93)* 0.71 (0.49-1.03) 0.62 (0.41-0.93)*
≥40 72 (8.6) 0.74 (0.44-1.24) 0.82 (0.49-1.39) 0.96 (0.56-1.65) 0.94 (0.52-1.69)
Waist circumference tertiles (cm)
M: <98.5, F < 90 197 (33.2) 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
M: 98.5-110, F: 90-101 198 (33.3) 1.23 (0.83-1.82) 1.14 (0.75-1.65) 1.31 (0.86-1.97) 0.99 (0.63-1.56)
M > 110, F: >101 199 (33.5) 0.87 (0.57-1.33) 0.89 (0.58-1.35) 1.00 (0.64-1.57) 0.87 (0.54-1.41)
Conicity index tertiles
<1.291 196 (33.3) 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
1.291-1.372 196 (33.3) 1.14 (0.74-1.80) 1.03 (0.67-1.59) 1.03 (0.65-1.63) 1.13 (0.68-1.86)
>1.372 196 (33.3) 1.59 (1.05-2.39)* 1.46 (0.96-2.20) 1.39 (0.88-2.22) 1.16 (0.69 -1.95)
Results expressed as number (percentage) and hazard ratio (95 % confidence interval)
Model 1: Adjusted for age
Model 2: Adjusted for age, gender, race (Caucasian vs. Non-Caucasian)
Model 3: Model 2 + estimated glomerular filtration rate, proteinuria, cause of chronic kidney disease, diabetes status
*P ≤ 0.05, **P ≤ 0.01
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ConI was also found to not be independently predict-
ive of kidney disease progression or death in patients
with stages 3–4 CKD. Although there have been no
prior studies of ConI as a prognostic factor in non-
dialysis CKD patients, Evans et al. reported that ConI
was more strongly correlated with risk factors for car-
diovascular disease and CKD progression, including
eGFR, proteinuria, uric acid and systolic blood pres-
sure, than WC or BMI [20]. A small study of 104 pre-
dialysis CKD patients found that increasing ConI was
associated with greater eGFR reduction over a 12 month
period [21]. Furthermore, a study of 173 haemodialysis
patients demonstrated an association between elevated
ConI and mortality, which was no longer apparent
following adjustment for markers of inflammation and
malnutrition [18].
This study has a number of important limitations. Firstly,
the observational design meant that a causal relationship
could not be inferred from the observed associations.
Secondly, the small sample size and limited study duration
(median follow-up 3.23 years) meant that the possibility of
a type 2 statistical error could not be excluded, particularly
in the extreme BMI categories (<18.5 and ≥40 kg/m2).
Nevertheless, 903 individuals participated in the study and
224 (25 %) experienced a primary event. Thirdly, there was
limited adjustment for comorbidities in the models, such
that the possibility of residual confounding could not be
excluded. Fourthly, while there was a standard protocol
used to measure waist circumference by trained health
practitioners, the risk of inter-observer variation was not
formally evaluated. Fifthly, the assessment of abdominal
girth may have been confounded in patients with polycystic
Fig. 3 Hazard Ratios for the Composite Outcome (a) and Mortality (b) for BMI Categories. A U-shaped association is evident between BMI categories
and hazard ratios for both the composite outcome and mortality, in stage 3–4 CKD patients. Hazard ratios with 95 % CIs shown for Cox regression
models: crude, model 1 (age-adjusted), model 2 (model 1 plus gender and race-adjusted), model 3 (model 2 plus estimated glomerular filtration rate,
proteinuria, cause of chronic kidney disease, diabetes status)
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kidney disease, although such patients comprised less than
3 % of the total population. Sixthly, WC and ConI data
were missing in approximately one-third of patients,
which may have introduced bias. Finally, there were
very few Aboriginal or Torres Strait Islander peoples
within the study cohort, such that the results of the
current investigation may not be generalisable to this
high risk population [37].
Conclusion
This study demonstrated that, in an Australian stage 3–4
CKD population, BMI in the overweight and obesity classes
I/II range is associated with reduced risks of progression of
renal disease and mortality, and that adjusting for WC does
not significantly alter this association. Alternative anthropo-
metric measures of central obesity (WC and ConI) were
not significantly associated with disease progression or
mortality in this population, however BMI may be valuable
for risk-stratification of newly referred CKD patients.
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Table 3 Association between baseline obesity parameters and all-cause mortality in stage 3–4 chronic kidney disease. Comparison
performed using Cox proportional hazards modelling to compare body mass index, waist circumference and conicity index with
all-cause mortality
HR (95 % CI)
No. (%) Crude Model 1 Model 2 Model 3
Body mass index (kg/m2)
<18.5 15 (1.8) 0.23 (0.03-1.67) 0.39 (0.05-2.89) 0.49 (0.07-3.58) 1.03 (0.14-7.80)
18.5-24.9 174 (20.7) 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
25-29.9 293 (34.8) 0.56 (0.37-0.86)** .54 (0.35-0.83)** 0.57 (0.36-0.90)* 0.50 (0.30-0.83)**
30-39.9 288 (34.2) 0.53 (0.34-0.82)** .63 (0.41-0.98)* 0.70 (0.44-1.11) 0.69 (0.41-1.15)
≥40 72 (8.6) 0.86 (0.49-1.54) 1.40 (0.77-2.54) 1.71 (0.93-3.16) 1.74 (0.89-3.40)
Waist circumference tertiles (cm)
M: <98.5, F < 90 197 (33.2) 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
M: 98.5-110, F: 90-101 198 (33.3) 1.21 (0.75-1.95) 1.04 (0.65-1.68) 1.18 (0.72-1.95) 0.90 (0.52-1.58)
M > 110, F: >101 199 (33.5) 0.83 (0.50-1.40) 1.07 (0.59-1.71) 1.09 (0.62-1.92) 1.00 (0.54-1.86)
Conicity index tertiles
<1.291 196 (33.3) 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent)
1.291-1.372 196 (33.3) 1.61 (0.93-2.77) 1.29 (0.75-2.22) 1.33 (0.74-2.36) 1.67 (0.89-3.13)
>1.372 196 (33.3) 1.85 (1.09-3.15)* 1.57 (0.92-2.67) 1.53 (0.84-2.79) 1.31 (0.66-2.58)
Results expressed as number (percentage) and hazard ratio (95 % confidence interval)
Model 1: Adjusted for age
Model 2: Adjusted for age, gender, race (Caucasian vs. Non-Caucasian)
Model 3: Model 2 + estimated glomerular filtration rate, proteinuria, cause of chronic kidney disease, diabetes status
*P ≤ 0.05, **P ≤ 0.01
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